Advertisement
Screener

Fusion Pharmaceuticals Inc. Net Income

Fusion Pharmaceuticals Inc. Net Income

Fusion Pharmaceuticals Inc. reported Net Income of -$33.67 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-07.

Discontinued › Income Statement › Net Income

us-gaap:NetIncomeLoss · last filed 2024-05-07

  • Fusion Pharmaceuticals Inc. net income (loss) attributable to parent for the quarter ending 2024-03-31 was -$33.67M.
  • Fusion Pharmaceuticals Inc. net income (loss) attributable to parent for the quarter ending 2023-12-31 was -$28.18M.
  • Fusion Pharmaceuticals Inc. net income (loss) attributable to parent for the quarter ending 2023-09-30 was -$17.25M.
  • Fusion Pharmaceuticals Inc. net income (loss) attributable to parent for the quarter ending 2023-06-30 was -$25.18M.
  • Fusion Pharmaceuticals Inc. net income (loss) attributable to parent for fiscal 2023 was -$94.90M.
  • Fusion Pharmaceuticals Inc. net income (loss) attributable to parent for fiscal 2022 was -$87.61M.
  • Fusion Pharmaceuticals Inc. net income (loss) attributable to parent for fiscal 2021 was -$81.05M.
  • Fusion Pharmaceuticals Inc. net income (loss) attributable to parent for fiscal 2020 was -$78.33M.
Period endNet Income (Loss) Attributable to Parent 3 monthNet Income (Loss) Attributable to Parent 6 monthNet Income (Loss) Attributable to Parent 9 monthNet Income (Loss) Attributable to Parent 12 month
2024-03-31-$33.67M
10-Q · filed 2024-05-07
-$61.85M
derived: sum of 2 quarters · filed 2024-05-07
-$79.10M
derived: sum of 3 quarters · filed 2024-05-07
-$104.28M
derived: sum of 4 quarters · filed 2024-05-07
2023-12-31-$28.18M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20
-$45.43M
derived: sum of 2 quarters · filed 2024-03-20
-$70.61M
derived: sum of 3 quarters · filed 2024-03-20
-$94.90M
10-K · filed 2024-03-20
2023-09-30-$17.25M
10-Q · filed 2023-11-07
-$42.43M
derived: sum of 2 quarters · filed 2023-11-07
-$66.72M
10-Q · filed 2023-11-07
-$91.33M
derived: sum of 4 quarters · filed 2024-05-07
2023-06-30-$25.18M
10-Q · filed 2023-11-07
-$49.47M
10-Q · filed 2023-08-08
-$74.08M
derived: sum of 3 quarters · filed 2024-05-07
-$98.10M
derived: sum of 4 quarters · filed 2024-05-07
2023-03-31-$24.29M
10-Q · filed 2024-05-07
-$48.91M
derived: sum of 2 quarters · filed 2024-05-07
-$72.92M
derived: sum of 3 quarters · filed 2024-05-07
-$91.99M
derived: sum of 4 quarters · filed 2024-05-07
2022-12-31-$24.62M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20
-$48.63M
derived: sum of 2 quarters · filed 2024-03-20
-$67.70M
derived: sum of 3 quarters · filed 2024-03-20
-$87.61M
10-K · filed 2024-03-20
2022-09-30-$24.01M
10-Q · filed 2023-11-07
-$43.09M
derived: sum of 2 quarters · filed 2023-11-07
-$62.99M
10-Q · filed 2023-11-07
-$80.23M
derived: sum of 4 quarters · filed 2023-11-07
2022-06-30-$19.07M
10-Q · filed 2023-11-07
-$38.98M
10-Q · filed 2023-08-08
-$56.22M
derived: sum of 3 quarters · filed 2023-11-07
-$75.65M
derived: sum of 4 quarters · filed 2023-11-07
2022-03-31-$19.91M
10-Q · filed 2023-11-07
-$37.15M
derived: sum of 2 quarters · filed 2023-11-07
-$56.57M
derived: sum of 3 quarters · filed 2023-11-07
-$83.43M
derived: sum of 4 quarters · filed 2023-11-07
2021-12-31-$17.24M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16
-$36.66M
derived: sum of 2 quarters · filed 2023-03-16
-$63.52M
derived: sum of 3 quarters · filed 2023-03-16
-$81.05M
10-K · filed 2023-03-16
2021-09-30-$19.43M
10-Q · filed 2022-11-08
-$46.28M
derived: sum of 2 quarters · filed 2022-11-08
-$63.81M
10-Q · filed 2022-11-08
-$77.20M
derived: sum of 4 quarters · filed 2022-11-08
2021-06-30-$26.85M
10-Q · filed 2022-11-08
-$44.38M
10-Q · filed 2022-08-09
-$57.77M
derived: sum of 3 quarters · filed 2022-11-08
-$67.76M
derived: sum of 4 quarters · filed 2022-11-08
2021-03-31-$17.53M
10-Q · filed 2022-11-08
-$30.91M
derived: sum of 2 quarters · filed 2022-11-08
-$40.91M
derived: sum of 3 quarters · filed 2022-11-08
-$85.64M
derived: sum of 4 quarters · filed 2022-11-08
2020-12-31-$13.38M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17
-$23.38M
derived: sum of 2 quarters · filed 2022-03-17
-$68.11M
derived: sum of 3 quarters · filed 2022-03-17
-$78.33M
10-K · filed 2022-03-17
2020-09-30-$9.99M
10-Q · filed 2021-11-09
-$54.73M
derived: sum of 2 quarters · filed 2021-11-09
-$64.95M
10-Q · filed 2021-11-09
-$73.15M
derived: sum of 4 quarters · filed 2021-11-09
2020-06-30-$44.73M
10-Q · filed 2021-11-09
-$54.95M
10-Q · filed 2021-08-10
-$63.16M
derived: sum of 3 quarters · filed 2021-11-09
-$63.76M
derived: sum of 4 quarters · filed 2021-11-09
2020-03-31-$10.22M
10-Q · filed 2021-11-09
-$18.43M
derived: sum of 2 quarters · filed 2021-11-09
-$19.02M
derived: sum of 3 quarters · filed 2021-11-09
-$22.48M
derived: sum of 4 quarters · filed 2021-11-09
2019-12-31-$8.21M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25
-$8.80M
derived: sum of 2 quarters · filed 2021-03-25
-$12.26M
derived: sum of 3 quarters · filed 2021-03-25
-$16.19M
10-K · filed 2021-03-25
2019-09-30-$594.00K
10-Q · filed 2020-11-10
-$4.05M
derived: sum of 2 quarters · filed 2020-11-10
-$7.98M
10-Q · filed 2020-11-10
2019-06-30-$3.46M
10-Q · filed 2020-11-10
-$7.39M
10-Q · filed 2020-08-11
2019-03-31-$3.93M
10-Q · filed 2020-11-10